The firm remains a symbol of the rise of the Chinese biotech sector.
A well-executed secondary offering bodes well for the future, indicative of institutional interest and future business development.
The pipeline continues to progress with pivotal studies initiated for key assets.
In-licensing of Mirati Therapeutics´ sitravatinib was a wise move and I expect several such similar deals to take place throughout 2018.
While the chart appears currently extended, the stock remains a long term buy in biotech for which readers should ¨buy the dips¨.
Shares of BeiGene (BGNE) have tripled since initially presenting the idea to readers in April last year. After the stock soared 85% I published an update piece, noting that management at the China-based firm continued to execute as trials involving key clinical assets progressed and we looked at the specifics of their lucrative collaboration with Celgene (CELG). When the stock fell back down to the low $80s as a result of general weakness in the biotech sector, I suggested that readers ¨buy the dip¨ as the fundamental thesis appeared unchanged and key institutional investors (especially Baker Brothers) added to their positions.